ClinicalTrials.gg
RecruitingNCT06600295ONDESUpdated Oct 8, 2026

Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action

An observational study in Oropharynx Cancer, Oral Cavity and Colon Cancer, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
306
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Oropharyngeal Neoplasms with a site in France — 7 open to participants now, 9 under way, 4 of them phase 3. Oropharyngeal Neoplasms · France.

Started
2024
with 1 other
Observational
9 of 31
1 open now
Registered
26th of 31
by date

Among the 31 studies in Oropharyngeal Neoplasms with a site in France, this one is one of 2 that started in 2024, is one of 9 observational ones, and was the 26th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

7 of the 31 studies in Oropharyngeal Neoplasms with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Oropharyngeal Neoplasms with a site in France, or all of them as a file.
02

Study summary

Cancers of the upper aerodigestive tract account for around 4% of all malignant tumours worldwide. Colon and liver cancer are the most common digestive cancers. The epidemiology of liver cancer is changing, and the number of deaths from liver cancer has increased by 25% worldwide. In France, around 19,000 cancers of the upper aerodigestive tract and 88,000 new cases of digestive cancer are diagnosed each year (colon cancer remains the most common). Patients with these two types of cancer are at particularly high risk of undernutrition.

In cancer patients, changes in diet may result from constraints linked to the cancer or possible after-effects, but also from personal choices (for example, adopting a healthier diet). Cancer and its treatment lead to changes such as increased nutritional requirements and hypercatabolism, or sensory changes (taste and smell), reducing pleasure and food intake. These problems will impair quality of life and intensify undernutrition, a major problem in the management of the disease since it increases the risk of complications, therapeutic failure and mortality. It is estimated that 10-20% of deaths in cancer patients are attributable to the consequences of undernutrition rather than to the disease itself. In the VICAN study, 41% of patients changed their diet after diagnosis: 29% because of changes in taste and 82% to have a healthier diet. These changes were associated with the treatment received, the presence of sequelae and anxiety.

Taste and smell disorders are common in different types of cancer (any solid or haematological type) and treatments (chemotherapy, radiotherapy and surgery. The mechanisms involved in sensory changes are not fully understood, especially in cancer, and with different types and treatments. Several hypotheses have been proposed: altered expression of enzymes of the oral sphere, altered expression of sensory receptors, saliva composition and function, and impact of the oral microbiota.

The early identification of undesirable effects linked to nutrition, and the early or anticipated diagnosis of undernutrition are important issues in the management of cancer patients. The pleasure (or displeasure) produced by food guides desire and eating behaviour. The mechanisms involved are linked to hedonic sensations: conditioned satiety, specific sensory satiety, negative alliesthesia and the reward system (hedonic system). The latter is influenced by the environment and can be consciously controlled, with several dimensions: liking (the patient likes or dislikes a given food) and wanting (evaluates the desire to consume a given food at a given moment). All these parameters, together with sensory and dietary learning throughout life (habits, beliefs and constraints), influence food preferences and therefore eating behaviour. Individual sensitivities and the personal history of the disease (treatment and care pathway, sequelae, presence of co-morbidities, etc.) must therefore be taken into account when setting up preventive actions for cancer patients. It seems important to explore these factors, the experience of patients and the consequences for eating behaviour in daily life, in order to improve support and communication with healthcare professionals, as well as prevention and early detection of undernutrition. It would be interesting to conduct more in-depth studies on nutritional status, quality of life and changes in taste and smell, which in most studies have been considered separately.

03

Conditions studied

  • Oropharynx Cancer
  • Oral Cavity
  • Colon Cancer
  • Liver Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible patients will be identified :

  • at the department\'s multidisciplinary consultation meetings
  • during consultations with their referring doctor (ENT or gastroenterologist)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient :

  • With newly diagnosed cancer of the oropharynx, oral cavity, colon or liver (at any stage).
  • For whom treatment has been decided including radiotherapy, chemotherapy, immunotherapy and/or surgery.
  • Able to follow all study procedures in accordance with the protocol.
  • Have given their oral, free and to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Person not affiliated with national health insurance system
  • Person subject to a legal protection measure (curatorship, guardianship)
  • Pregnant women, women in labour or breastfeeding mothers
  • Adults who is unable to give consent
  • Minors
  • Person unable to read, speak, write and understand French
  • Patients with neuro-cognitive disorders (post-stroke, dyslexia, dyspraxia) or neuro-psychiatric disorders (dementia, autism) that make it impossible to assess taste sensoriality.
  • Patients with olfactory or gustatory disorders documented prior to the disease
  • Patient with another cancer currently being treated
  • Patients with a systemic disease or physical trauma affecting taste perception
  • Patients with kidney failure
  • Patients with sinonasal polyposis
  • Patients undergoing treatment
  • Patients with an estimated of less than 3 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
306 participants (estimated)
Patient registry
No

Groups and cohorts

  • patients with cancer of the oral cavity/oropharynx

    115 patients with cancer of the oral cavity/oropharynx

    Other: tests/questionnaires · Biological: biological samples · Other: evaluation

  • colon cancer patients

    123 colon cancer patients

    Other: tests/questionnaires · Biological: biological samples · Other: evaluation

  • patients with liver cancer

    68 patients with liver cancer

    Other: tests/questionnaires · Biological: biological samples · Other: evaluation

Interventions

  • Othertests/questionnaires

    EVA, LFPQ-fr, Taste strips, ETOC 6-items, CiTAS, Fr-sQOD, WHOQOL-Bref, HADS

  • Biologicalbiological samples

    blood, saliva, tongue mucus

  • Otherevaluation

    strength tests using handgrip tests, chair lifts or walking speed and sarcopenia tests for the over-70s

06

What researchers measure

Primary outcomes

  1. The presence or absence of undernutrition

    Time frame: Through study completion, an average of 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2031, 84 months after the start.

Of 47 observational studies under Oropharyngeal Neoplasms, half reached primary completion within 110 months of starting (the median), counting those still running; a quarter within 40. This study's planned 84 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Sep 2027 → Sep 2031 and completion Sep 2027 → Sep 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Sep 19, 2024
StartActual
Sep 6, 2024
Primary completionEst.
Sep 2031was Sep 2027
CompletionEst.
Sep 2031was Sep 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2027→Sep 2031
Oct 8, 2026
Study completion
Sep 2027→Sep 2031
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Sep 2027→Sep 2031
    Study completion Sep 2027→Sep 2031
    + 4 other changes: verification date, description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06600295
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 6, 2024
Primary completion
Sep 2031 (estimated)
Completion
Sep 2031 (estimated)
Last update
Oct 8, 2026

Study contacts

Vanessa COTTET
Contact
Vanessa.cottet@u-bourgogne.fr
0380393487 ext. +33

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion